Literature DB >> 8678060

Accurate measurement of impaired glomerular filtration using single-dose oral cimetidine.

J S Zaltzman1, C Whiteside, D C Cattran, F M Lopez, A G Logan.   

Abstract

To improve the validity of a timed creatinine clearance as a measure of glomerular filtration rate (GFR), we investigated whether a single 800-mg dose of oral cimetidine was sufficient to inhibit tubular secretion of creatinine (TScr). Forty-five 3-hour timed creatinine clearances (Clcr) with single 800-mg dose oral cimetidine (TCC) in 17 renal transplant recipients with marked renal function impairment (creatinine 2.0 to 7.1 mg/dL) were compared with simultaneous [125I]-iothalamate GFR (Cliothal). For comparison, 13 timed Clcr without cimetidine (TC), and 36 24-hour Clcr were performed. The TCC was the most accurate: the ratio (mean +/- SD) of TCC:Cliothal was 1.12 +/- 0.02, compared with 1.33 +/- 0.08 for Clcr:Cliothal and 1.53 +/- 1.02 for TC:Cliothal. The difference between Cliothal and TCC was small over the range of GFRs tested (mean +/- 2 SD), 0.9 +/- 2.5 mL/min/1.73 m2. The intraclass correlation (R) for within-subject reproducibility of the TCC in five subjects was 0.8 (95 percent CI; 0.5, 0.9), and in 11 subjects who had at least three GFR determinations over 24 weeks, the TCC was as responsive to change in GFR as Cliothal. There was an inverse relationship between fractional excretion of cimetidine and GFR (r2 = -0.70), suggesting increased tubular secretion of cimetidine with decreasing GFR. In conclusion, a single 800-mg oral dose of cimetidine was effective in inhibiting TScr such that the TCC was an accurate, reproducible, and responsive test of GFR.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8678060     DOI: 10.1016/s0272-6386(96)90160-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

Review 1.  Measurement of renal function during drug development.

Authors:  D Craig Brater
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

2.  Measurement Error as Alternative Explanation for the Observation that CrCl/GFR Ratio is Higher at Lower GFR.

Authors:  Xuehan Zhang; Charles E McCulloch; Feng Lin; Yen-Chung Lin; Isabel Elaine Allen; Nisha Bansal; Alan S Go; Chi-Yuan Hsu
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-03       Impact factor: 8.237

3.  Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.

Authors:  Evelyn M Brosnan; Andrew J Weickhardt; Xian Lu; Delee A Maxon; Anna E Barón; Michel Chonchol; D Ross Camidge
Journal:  Cancer       Date:  2013-11-20       Impact factor: 6.860

4.  A role for the organic anion transporter OAT3 in renal creatinine secretion in mice.

Authors:  Volker Vallon; Satish A Eraly; Satish Ramachandra Rao; Maria Gerasimova; Michael Rose; Megha Nagle; Naohiko Anzai; Travis Smith; Kumar Sharma; Sanjay K Nigam; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-15

Review 5.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

6.  Major contribution of tubular secretion to creatinine clearance in mice.

Authors:  Christoph Eisner; Robert Faulhaber-Walter; Yaohui Wang; Asada Leelahavanichkul; Peter S T Yuen; Diane Mizel; Robert A Star; Josephine P Briggs; Mark Levine; Jurgen Schnermann
Journal:  Kidney Int       Date:  2009-12-23       Impact factor: 10.612

Review 7.  Estimating Creatinine Clearance in the Nonsteady State: The Determination and Role of the True Average Creatinine Concentration.

Authors:  Sheldon Chen; Robert Chiaramonte
Journal:  Kidney Med       Date:  2019-07-09

8.  Tubular secretion of creatinine and kidney function: an observational study.

Authors:  Xuehan Zhang; Andrew D Rule; Charles E McCulloch; John C Lieske; Elaine Ku; Chi-Yuan Hsu
Journal:  BMC Nephrol       Date:  2020-03-30       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.